EXAS+121.00%10.0%
GH+178.00%10.0%
GRAL+132.30%10.0%
ICAD0.00%10.0%
MASS+65.58%10.0%
NVCR+37.57%10.0%
PACB-2.17%10.0%
PSNL+280.54%10.0%
RDNT+9.59%10.0%
STLN+72.56%10.0%
As of Aug 24, 2026, 4:53 AM ET
MedTech Long '25: Cancer Diagnostics, Platforms & Care Constituents
908 Devices Inc.MASS | 10.0% | 3.19% | 6.69% | 49.58% | 33.33% | 103.43% | 54.78% | 173.85% | 159.85% | -67.81% | 65.58% | $438.2M |
Exact Sciences CorporationEXAS | 10.0% | 0.00% | 0.00% | 0.00% | 0.00% | 3.30% | 1.48% | 135.44% | 75.73% | 7.50% | 121.00% | $20.03B |
GRAIL Inc.GRAL | 10.0% | 2.01% | 5.38% | 17.25% | 16.02% | -7.07% | 49.43% | 204.28% | 416.16% | 291.44% | 132.30% | $3.41B |
Guardant Health, Inc.GH | 10.0% | 1.67% | 3.39% | 15.86% | 5.37% | 67.11% | 81.78% | 292.48% | 488.18% | 57.26% | 178.00% | $22.91B |
iCAD, Inc.ICAD | 10.0% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -82.36% | 0.00% | $56.6M |
Novocure LtdNVCR | 10.0% | -3.77% | -3.17% | -3.12% | 15.23% | 32.25% | 25.09% | -4.68% | -5.11% | -87.34% | 37.57% | $1.99B |
Pacific Biosciences of California, Inc.PACB | 10.0% | 9.76% | 18.42% | -0.74% | -3.57% | -27.81% | -19.64% | 6.30% | -13.46% | -95.34% | -2.17% | $419.3M |
Personalis, Inc.PSNL | 10.0% | 8.89% | 31.10% | 56.03% | 45.18% | 130.90% | 102.87% | 416.29% | 207.87% | -1.71% | 280.54% | $1.96B |
RadNet, Inc.RDNT | 10.0% | -0.30% | 0.63% | 24.77% | 20.45% | 7.67% | 10.04% | 46.30% | 18.18% | 152.37% | 9.59% | $6.04B |
The Oncology Institute, Inc.STLN | 10.0% | 0.00% | 5.57% | 31.33% | 34.57% | 83.71% | 126.30% | 341.89% | 1647.77% | -34.50% | 72.56% | $646.4M |
| Theme return | — | 2.15% | 6.80% | 15.30% | 15.99% | 44.90% | 44.39% | 179.24% | 264.03% | 64.42% | 109.82% | — |
| Average | 10.0% | 2.15% | 6.80% | 19.10% | 16.66% | 39.35% | 43.21% | 161.21% | 299.52% | 13.95% | 89.50% | $5.79B |
| Median | 10.0% | 0.84% | 4.39% | 16.56% | 15.63% | 19.96% | 37.26% | 154.64% | 117.79% | -18.10% | 69.07% | $1.98B |
| Std Dev | 0.0% | 3.99% | 9.85% | 20.26% | 15.88% | 50.79% | 45.95% | 144.34% | 480.06% | 117.83% | 85.74% | $8.05B |
| Min | 10.0% | -3.77% | -3.17% | -3.12% | -3.57% | -27.81% | -19.64% | -4.68% | -13.46% | -95.34% | -2.17% | $56.6M |
| Max | 10.0% | 9.76% | 31.10% | 56.03% | 45.18% | 130.90% | 126.30% | 416.29% | 1647.77% | 291.44% | 280.54% | $22.91B |
| % Positive Tickers | 50.00% | 70.00% | 60.00% | 70.00% | 70.00% | 80.00% | 80.00% | 70.00% | 40.00% | 80.00% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
MedTech Long '25: Cancer Diagnostics, Platforms & Care tracks 10 publicly listed stocks in this theme: EXAS, GH, GRAL, ICAD, MASS, NVCR, PACB, PSNL, RDNT, STLN. See the constituent table for details.